| Dec'19 | Dec'18 | |||||
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
17,640 | 4,943 | |||||
General and administrative | ||||||
9,087 | 3,672 | |||||
Total operating expenses | ||||||
26,727 | 8,615 | |||||
Loss from operations | ||||||
-26,727 | -8,615 | |||||
Other (expense) income, net: | ||||||
Interest expense | ||||||
279 | 2,558 | |||||
Interest income | ||||||
1,391 | 340 | |||||
Other expense, net | ||||||
15 | - | |||||
Change in fair value of Biocon anti-dilution right | ||||||
- | 2,417 | |||||
Total other (expense) income, net | ||||||
1,127 | -4,635 | |||||
Net loss | ||||||
-25,600 | -13,250 | |||||
Other comprehensive income, net: | ||||||
Unrealized gain on available-for-sale securities, net | ||||||
44 | 5 | |||||
Foreign currency translation gain | ||||||
-28 | - | |||||
Total other comprehensive income, net | ||||||
16 | 5 | |||||
Comprehensive loss | ||||||
-25,584 | -13,245 | |||||
Net loss per share, basic and diluted | ||||||
-1.47 | -1.09 | |||||
Weighted-average common shares outstanding, basic and diluted | ||||||
17,378 | 12,190 | |||||